Ann: Notification regarding unquoted securities - KZA, page-4

Effort and hard work is required from all Board members - is the reasonable request from shareholders. Especially at nearly $200k per annum, as non-executive Chairman.

To justify your annual remuneration Mr Ross - and in view of all your other positions....maybe it is time to consider your continuing role in Kazia Therapeutics (especially in view of the performance of the share price - which is in direct contrast to your own stated words - of growing shareholder value)

	Column 1
0

	Column 1	Column 2
0	Column 1 0 Current positions of Iain Gladstone Ross

	Column 1	Column 2	Column 3	Column 4	Column 5	Column 6	Column 7	Column 8	Column 9	Column 10	Column 11	Column 12	Column 13
0	{colgroup}{col}{/col}{col}{/col}{col}{/col}{/colgroup}Name	Title	Since Silence Therapeutics plc	Non-Executive Chairman	2020 Kazia Therapeutics Limited(Biotechnology & Medical Research)	Non-Executive Chairman	2017 ReNeuron Group plc(Biotechnology & Medical Research)	Non-Executive Chairman	2021 BiVictriX Therapeutics Plc(Biotechnology & Medical Research)	Non-Executive Director	2023 Motif Bio plc(Biotechnology & Medical Research)	Non-Executive Chairman	2021

[/table]